Healthcare and Pharmaceutical Sector

Alnylam Pharmaceuticals (ALNY) got a double dose of analyst love this week after Ionis Pharmaceuticals' Phase 3 ATTR-CM trial — a late-stage study testing a treatment for a heart condition called transthyretin amyloid cardiomyopathy — failed, removing a key competitor from Alnylam's most lucrative drug territory. Raymond James raised its price target to $468 from $420, keeping an Outperform rating, arguing the Ionis setback both strengthens Alnylam's pricing power and improves the long-term outlook for its TTR silencer franchise — a class of RNA-based drugs that quiet the gene responsible for the disease. Morgan Stanley followed with a bump to $400 from $370, though it held its Equal Weight rating, a notably more cautious stance that reflects Wall Street's split verdict on how much of this tailwind is already priced in. H.C. Wainwright, which still holds a Buy, projects Alnylam's TTR franchise could exceed $20 billion in annual revenues by 2040 — a number that puts the long-term bull case in sharp relief even as near-term estimates for its Amvuttra drug were trimmed (Yahoo Finance).

Biogen's experimental Alzheimer's drug diranersen cleared a meaningful hurdle in a Phase 2 trial — a mid-stage study designed to test safety and early efficacy — by slowing patients' cognitive decline at rates roughly comparable to already-approved therapies on the market, according to STAT News. The drug also demonstrated an ability to lower tau levels, a protein that forms toxic tangles in the brain and is closely linked to memory loss and disease progression, giving researchers a biological marker to track alongside the clinical results. Alzheimer's specialists noted that different doses produced consistent improvements versus placebo, which strengthens the argument that the drug is genuinely affecting the disease rather than generating statistical noise. Biogen now has a credible case to advance to a Phase 3 pivotal trial — the large-scale study required for regulatory approval — though experts caution that the real verdict on diranersen won't arrive until that larger data set is in hand (STAT News).

Johnson & Johnson (JNJ) is expected to report Q2 earnings on July 15, with Wall Street forecasting earnings per share (EPS — profit divided by total shares outstanding) of $2.85, roughly 3% above last year's figure, according to Seeking Alpha. The main headwind is Stelara, J&J's blockbuster immunology drug, which is losing ground to cheaper biosimilar competitors (copycat biologics that erode branded drug sales). Despite that pressure, analysts remain constructive on the broader portfolio, suggesting J&J's diversified medtech and pharmaceutical mix is doing enough heavy lifting. A solid print here would signal that big pharma can manage patent cliffs better than the market fears — worth watching when the numbers drop before the opening bell.